Kornimate/medical-research-clean huggingface dataset:
temperature recording in lungs of volunteers with and without pulmonary diseases

Conditions: Temperature Change, Body; Bronchiectasis; Heat Exposure; Heat

Summary: the purpose of the project is to estimate the air temperature in the lungs after a change from room temperature (25℃) to an environment with a constant temperature of 88-92℃ in resp. lung-healthy persons and persons with bronchiectasis.

heat is a widely available therapeutic modality and is often used for recovery after physical activity and pain treatment, and sauna bathing is a form of whole body thermotherapy ranging from 80-100 ℃ and low humidity of 10-20%. the heat load in a sauna has been shown to activate several beneficial physiological effects, and no adverse effects on the lungs have been demonstrated. it is unknown how much the air temperature in the lower respiratory tract (bronchial tree) in humans rises to under surroundings of 88-92℃. this is an observational, clinical trial investigating the changes in air temperature at different bronchial segments in both lungs under surroundings of 88-92℃ resp. in lung-healthy persons and persons with bronchiectasis.

Eligibility criteria:
lung-healthy group: inclusion criteria: * age ≥ 18 years * competent and capable * forced expiratory volume in the first second (fev1)\>1,0 l * does not suffer from bronchiectasis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, sarcoidosis, active lung infection (past 30 days) or lung cancer exclusion criteria: * allergy to lidocaine and/or midazolam * contraindications to bronchoscopy\* * previous severe laryngospasm (intubation requiring) * pregnancy/breastfeeding * severe linguistic problems or inability to give informed consent * severe mental illness that is not controlled with medication. nb: patients with controlled mental illness can be included and will be asked on an equal footing as others bronchiectasis group: inclusion criteria: * age ≥ 18 years * competent and capable * fev1\>1,0 l * have diagnosed bronchiectasis \[radiology verified and evaluated by pulmonary specialist\] exclusion criteria: * allergy to lidocaine and/or midazolam * contraindications to bronchoscopy\* * previous severe laryngospasm (intubation requiring) * pregnancy/breastfeeding * severe linguistic problems or inability to give informed consent * severe mental illness that is not controlled with medication. nb: patients with controlled mental illness can be included and will be asked on an equal footing as others
endoscopic myotomy for the treatment of achalasia (motility disorder) of the esophagus - poem procedure

Conditions: Achalasia

Summary: endoscopic esophageal myotomy (poem), the research procedure, splits the lower esophageal sphincter muscle fibers from the inside of the esophagus, avoiding several abdominal incisions (belly area cuts), by using an endoscope to create a small cut at the most inner layer of the esophagus to expose the esophageal sphincter muscle fibers from the inside of the esophagus. the investigators are studying whether subjects who undergo endoscopic esophageal myotomy will have similar functional outcome, and at the same time less pain, scar formation and wound infection than with laparoscopic or open surgery.

the purpose of this research study is to find out more about a less invasive way of doing the surgical procedure (esophageal myotomy) to treat achalasia. achalasia is a disease of the esophagus, where the lower esophageal sphincter fails to relax, causing difficulty in swallowing. esophageal myotomy (heller myotomy) is surgically cutting the muscle fibers of the esophageal sphincter to allow passage of food into the stomach. esophageal myotomy is routinely done either by laparoscopic or open surgery. laparoscopic surgery requires several (about 4 to 5) small incisions in the abdomen to allow the camera and surgical instruments to be introduced into the abdominal cavity to perform the myotomy. in open surgery, a 6- to 8-inch abdominal incision is made to gain access to the abdominal cavity to perform the myotomy. endoscopic esophageal myotomy (poem), the research procedure, splits the lower esophageal sphincter muscle fibers from the inside of the esophagus, avoiding several abdominal incisions. the researchers are investigating how safe endoscopic esophageal myotomy is and how well it works. additionally, the researchers will assess the level of pain and the amount of scarring subjects has after this surgery.

Eligibility criteria:
inclusion criteria: * diagnosis of achalasia * age 18-65 * asa class 1-2 exclusion criteria: * pregnant women * any prior surgical or endoscopic treatment for achalasia except dilation less than 20 mm * patients who are taking immunosuppressive medications or are immunocompromised patients on blood thinners or aspirin or with history of bleeding disorders * asa class iii patients

Keywords: achalasia dysphagia endoscopic myotomy heller notes poem
combination of cetuximab, capecitabine, and oxaliplatin with or without bevacizumab

Conditions: Colorectal Neoplasms

Summary: the purpose of this study is to determine the objective response rate of patients with previously untreated metastatic colorectal cancer treated with the combination of cetuximab, capecitabine, and oxaliplatin with out without bevacizumab.

research has shown that the more drug treatments patients with cancer of the colon or rectum receive, the longer they live. one uses the drugs capecitabine and oxaliplatin which all patients on this study will receive. bevacizumab is an antibody which blocks blood flow to tumors and increases how long patients with colorectal cancer live. however, it can increase the risk of stroke and heart attack. bevacizumab is currently a standard part of treatment for colorectal cancer. cetuximab is an antibody which blocks a protein called egfr which shrinks colorectal cancer. it may be helpful with initial chemotherapy and with bevacizumab. one goal of this study is to find out the response rate (chance of tumor shrinking) with two treatments for colorectal cancer. all patients will get capecitabine, oxaliplatin and cetuximab. half will receive bevacizumab. all drugs in this study are approved to treat colorectal cancer. this research study is being done to find the best, safest way to combine these therapies.

Eligibility criteria:
inclusion criteria: * measurable metastatic adenocarcinoma of the colon or rectum * no prior systemic therapy for metastatic disease * adjuvant therapy must have been completed \>/=12 months prior to recurrence, prior radiotherapy permitted but must have been completed \> 6 months prior to study entry * must have tumor tissue available for egfr and thymidine phosphorylase evaluation * ecog ps 0-1 * age \>/= 18 * adequate organ function: wbc\>/=3,000, anc \>/=1,500, platelets\>/= 100,000, total bilirubin \ /= 50ml/min * negative pregnancy test w/in 72 hours of treatment for women of child bearing potential * ability to understand and willing to sign written icf * able to swallow and absorb oral medication exclusion criteria: * medical or psychiatric condition which would potentially pose risk to patient by participation (i.e. but not limited to:uncontrolled hypertension, mi w/in 6 months,cns disease, pregnancy or nursing) * history of neoplasm (other than non-metastatic skin cancer or carcinoma in situ of cervix) w/in 5 years * surgical procedure (not including closed biopsy or access port placement), open biopsy, significant traumatic injury w/in 28 days of registration or anticipation of need for surgical procedure while on study, fine needle aspiration or core biopsy w/in 7 days of registration * urine protein:creatinine ration \>/=1.0 at screening * evidence of bleeding diathesis or coagulopathy (in absence of anticoagulation) * prior severe infusion reaction to mab or allergic reaction to capecitabine or oxaliplatin * underlying neuropathy \>/= grade 2 * tia or cva w/in 6 months

Keywords: metastatic colorectal cancer initial therapy
treatment of non-dislocated midshaft both-bone fractures

Conditions: Fracture

Summary: the investigators created a randomized clinical trial to find out what kind of treatment is optimal for non-dislocated both-bone midshaft forearm fractures.

children who arrive at the emergency unit with a non-dislocated both-bone midshaft forearm fracture will be asked to join the trial. after informed consent we will do a randomization between 6 weeks above elbow cast and 3 weeks above elbow cast in combination with 3 weeks under elbow cast. outpatient clinic visits till a follow-up of 6 months. during these visits we will investigate: consolidation and dislocation on x-ray, function of both arms, complaints in daily living and complications.

Eligibility criteria:
inclusion criteria: * both-bone midshaft forearm fracture * age \< 16 years old exclusion criteria: * dislocation * fracture older than 1 week * no informed consent * refracture * open fracture (gustillo 2 and 3) * torus fractures of both ulna and radius

Keywords: fracture forearm midshaft child cast
radiomics analysis based on mri to detect brucella spondylitis

Conditions: Brucella Spondylitis

Summary: brucella spondylitis, an infectious spinal disease caused by the invasion of brucella bacteria into the body. its diagnosis relies mainly on laboratory and imaging tests. due to the limited diagnostic ability of x-ray and ct for brucella spondylitis, mri has become the main diagnostic tool. in recent years, functional magnetic resonance technology has demonstrated great advantages in the diagnosis and therapeutic evaluation of brucellosis spondylitis, which can provide pathophysiologic information about the disease and is also a noninvasive and noninvasive diagnostic tool with a broader application prospect. radiomics, an emerging approach, has also shown better diagnostic efficacy for this disease.

the investigators will incorporate 100 confirmed cases of brucella spondylitis (bs) patients diagnosed at affiliated hospital of inner mongolia medical university. the patients receive routine scan with a siemens skyra 3.0t mri scanner and the investigators collect clinical data and blood test results from the patients.the investigators segment the affected vertebral bodies by itk-snap software on stir images to create three-dimensional regions of interest. then use onekey software to extract radiomics features from the affected vertebral bodies. employed t-tests and lasso regression to select radiomics features. then separately use radiomics features and combining it with clinical information to build random vector machine(svm) and random forest(rf) models . all the models are constructed in the training set and their performance are evaluated on the validation set.

Eligibility criteria:
inclusion criteria: 1. outpatients/inpatients 2. age 18-70 years 3. meet diagnostic criteria for brucellosis 4. meet symptoms of brucellosis spondylitis 5. voluntarily sign an informed consent form 6. can cooperate with mri examination exclusion criteria: 1. patients with serious diseases of other systems 2. history of malignant tumors of the vertebral body 3. history of tuberculosis 4. contraindications to magnetic resonance imaging

Keywords: radiomics mri
apremilast pregnancy exposure registry

Conditions: Psoriatic Arthritis; Psoriasis

Summary: the purpose of the apremilast pregnancy exposure registry is to monitor planned and unplanned pregnancies exposed to apremilast and to evaluate the safety of this medication relative to specified pregnancy outcomes, and to evaluate potential effects of prenatal apremilast exposure on infant health status through one year of age.

the apremilast pregnancy exposure registry (registry) is a united states (u.s.) based registry designed to monitor planned or unplanned pregnancies exposed to apremilast when used to treat an approved indication in accordance with the current approved prescribing information, who reside in the u.s. or canada. the goal of the registry is to conduct an observational, controlled prospective cohort study that will involve follow-up of live born infants to one year of age. the primary objective of the registry is to evaluate any potential increase in the risk of major birth defects, specifically a pattern of anomalies, in apremilast exposed pregnancies compared to the primary comparison group of disease-matched unexposed pregnancies. secondary objectives are to evaluate the potential effect of exposure relative to the secondary comparison group of healthy pregnant women, and the effect of exposure on other adverse pregnancy outcomes including spontaneous abortion or stillbirth, preterm delivery, reduced infant birth size, a pattern of minor malformations, postnatal growth of live born children to one year of age, and incidence of serious or opportunistic infections or malignancies in live born children up to one year of age. the pregnancy exposure registry is sponsored by celgene corporation and is conducted by the organization of teratology information specialists (otis) research group and is administered by investigators at the coordinating site located at the university of california, san diego. the study is planned for seven years.

Eligibility criteria:
inclusion criteria: * pregnant exclusion criteria: -

Keywords: pregnancy apremilast otezla autoimmune disease psoriatic arthritis psoriasis tnf tumor necrosis factor birth outcome birth defect
biomarkers of ahsct

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as multiple sclerosis (ms), are incompletely understood. for such patients, autologous haematopoietic stem cell transplantation (ahsct) has been increasingly used as a highly successful one-off treatment for some patients. this treatment aims to delete the faulty immune system with a course of chemotherapy and then 'reboot' the immune system using a patients' own stem cells (a cell with the unique ability of being a building block to create many different cells in the body) to stop further damage. over the last 20 years more than 1800 patients with ms have been treated in europe with high levels of success. it may be more successful than disease modifying treatment but unfortunately, a small portion of people do not respond to this treatment optimally and continue to accumulate disability. there is a risk of side effects, restricted largely to the time of treatment, which necessitates the need to ensure appropriate patients are treated. whilst ahsct is a very effective therapy, it is still in its early phase of development, is not in widespread use, and there is incomplete knowledge regarding how it works and importantly, why it does not work in some patients, and how to monitor response to treatment. unfortunately, there is no way of detecting which patients will, and will not, benefit from the different treatments available or a way of monitoring the immune system to ensure further treatment is provided before irreversible damage occurs. this study will investigate the immune system which is found in the fluid surrounding the brain and spinal cord, blood and stool of patients undergoing ahsct and compare it to those receiving disease modifying treatment. this study will therefore further the understanding of biomarkers of ahsct to develop an awareness of how it can be refined, may improve monitoring of patients following treatment and permit the development of markers which can predict potential treatment success or failure before patients are exposed to the risks.


Eligibility criteria:
inclusion criteria: 1. diagnosis of a immune mediated neurological disease according to disease specific criteria (active treatment arm) or diagnosis of relapsing remitting multiple sclerosis (control arm). 2. treatment with autologous haematopoetic stem cell transplantation (active treatment arm) or high efficacy disease modifying treatment (control arm). 3. willing to provide biological samples for analysis and undergo clinical assessments for the duration of follow up. 4. able to understand english and provide informed consent. exclusion criteria: 1. inability to provide informed consent.

Keywords: multiple sclerosis ahsct autologous haematopoetic stem cell transplantation
study to assess differential sensitivity of 2 spatial working memory tests in schizophrenics treated with risperidone

Conditions: Schizophrenia; Psychotic Disorders

Summary: to assess the effect of risperidone 2 mg daily (qd) on the differential sensitivity of 2 spatial working memory tests (the gmlt and mdr) in non-agitated, drug-naive patients suffering from first-episode schizophrenia/schizophreniform disorder.


Eligibility criteria:
inclusion criteria: * male or female, 18 to 50 years old, antipsychotic-naive, non-agitated patients diagnosed with first-episode schizophrenia or schizophreniform disorder. exclusion criteria: * evidence or history of clinically significant medical or non-medical impairment that, in the opinion of the investigator, would affect the safety of the patient or interfere with the evaluation of the trial results; * patients who have a history of substance (which included alcohol) dependence within 12 months or abuse within 3 months of enrollment, or tested positive for an illicit drug on the screening urine toxicology test * pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception
factors influencing the results of treatment in patients with hernias of various localizations

Conditions: Inguinal Hernia; Femoral Hernia; Umbilical Hernia; Ventral Hernia; Chronic Pain; Acute Post Operative Pain; Recrrence Rate

Summary: the study attempts to quantify the relative risks for acute postoperative pain, complications rate, chronic postoperative pain (cpip) and recurrence rate after different methods of repair of groin, umbilical and incisional hernia depending on surgical technique, mesh type and fixation suture material. for this purpose the investigators will analyze data from the kalinigrad hernia registry (khr).


Eligibility criteria:
inclusion criteria: * all mesh and non-mesh repairs that have been registered in the khr from january 9, 2020, until december 31, 2023. exclusion criteria: * patients not having a 11-digit state-assigned personal insurance policy number. * parastomal hernia; * infected hernias;

Keywords: hernia register inguinal hernia femoral hernia umbilical hernia ventral hernia cpip postoperative complications chronic post-operative pain recurrence rate
swog-9342 chemotherapy in treating women enrolled in the swog-8897 clinical trial

Conditions: Breast Cancer; Cardiac Toxicity

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: this clinical trial is studying the effect of chemotherapy on heart function in treating women who have breast cancer with negative axillary lymph nodes and who are undergoing treatment on the swog-8897 clinical trial.

objectives: * compare the frequency of subclinical congestive heart failure by measuring resting muga at 5-8 and 10-11 years after randomization in women receiving adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, doxorubicin, and fluorouracil on protocol swog-8897. * estimate the frequency of late cardiac effects (congestive heart failure, cardiac ischemic events, and clinical symptoms) in these patients treated with these regimens. * monitor prospectively the incidence of annual cardiac events between the fifth and tenth year after randomization of these patients to these regimens. outline: this is a multicenter study. the treating physician completes patient cardiovascular and routine history and physical examination questionnaires at baseline and yearly. patients undergo resting muga scans at 5-8 and 10-11 years after registration on protocol swog-8897. the first scan must be performed within 3 months prior to enrollment or within 1 month after registration on the current study, and the second scan must be done in the tenth year of follow-up and within 3 months prior to enrollment or 1 month from the anniversary of registration on the current study. projected accrual: a total of 420 patients will be accrued for this study. after initial accrual is completed, approximately 50 additional patients will be accrued at 10 years.

Eligibility criteria:
disease characteristics: * women registered on arm i, ii, iii, or iv of protocol swog-8897 who have completed at least 1 course of assigned chemotherapy * completion of tamoxifen therapy not required * registration to current study required between 5.25-8 years or 10-11 years after randomization to protocol swog-8897 * patients must be diagnosed disease-free with no prior recurrence after registration on protocol swog-8897 * hormone receptor status: * not specified patient characteristics: age: * 18 and over sex: * female menopausal status: * pre- and postmenopausal performance status: * not specified life expectancy: * at least 5 years hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * pregnant or nursing women not eligible for nuclear medicine (muga) portion of study * fertile patients must use effective contraception during and for 1 month after muga prior concurrent therapy: biologic therapy: * not specified chemotherapy: * see disease characteristics * no prior chemotherapy for second primary malignancy endocrine therapy: * not specified radiotherapy: * no prior radiotherapy for second primary malignancy surgery: * not specified

Keywords: stage i breast cancer stage ii breast cancer ductal breast carcinoma cardiac toxicity
the clinical trial about treatment of benign uterus myoma by haifu focused ultrasound tumor therapeutic system

Conditions: Benign Uterine Tumor

Summary: uterine benign tumor including myoma is the most common female benign pelvic tumor. magnetic resonance-guided high-intensity focused ultrasound (mr-hifu) has been considered to be a minimal invasive treatment. the device used in this trial will be haifu focused ultrasound tumor therapeutic system. in this trial, the investigators will observe the possibility of complication and tumor response of treatment.


Eligibility criteria:
inclusion criteria: 1. benign uterine fibroids. 2. women over the age of 20. 3. abdominal circumference \<100 cm. 4. the largest fibroids are ≥ 4 cm. exclusion criteria: 1. pregnant women or those with positive pregnancy test results. 2. those with other pelvic diseases. 3. those with immune diseases. 4. there are unsuitable interfaces in the ultrasonic treatment path. 5. those with tumor calcification. 6. people with severe heart, blood vessel and kidney disease. 7. those with abnormal coagulation function and low platelets. 8. type iii fibroids according to funaki classification